Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Jun;36(6):1758-64.
doi: 10.2337/dc12-2388.
Collaborators
- PMID: 23704675
- PMCID: PMC3661790
- DOI: 10.2337/dc12-2388
Randomized Controlled Trial
Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial
TODAY Study Group. Diabetes Care. 2013 Jun.
Abstract
Objective: Type 2 diabetes increases cardiovascular risk. We examined lipid profiles and inflammatory markers in 699 youth with recent-onset type 2 diabetes in the TODAY clinical trial and compared changes across treatment groups: metformin alone (M), metformin plus rosiglitazone (M+R), and metformin plus intensive lifestyle program (M+L).
Research design and methods: Multiethnic youth with type 2 diabetes received M, M+R, or M+L. Statin drugs were begun for LDL cholesterol (LDL) ≥ 130 mg/dL or triglycerides ≥ 300 mg/dL. Lipids, apolipoprotein B (apoB), LDL particle size, high-sensitivity c-reactive protein (hsCRP), homocysteine, plasminogen activator inhibitor-1 (PAI-1), and HbA1c were measured over 36 months or until loss of glycemic control.
Results: LDL, apoB, triglycerides, and non-HDL cholesterol (HDL) rose over 12 months and then stabilized over the next 24 months. Participants with LDL ≥ 130 mg/dL or using LDL-lowering therapy increased from 4.5 to 10.7% over 36 months, while 55.9% remained at LDL goal (<100 mg/dL) over that time. Treatment group did not impact LDL, apoB, or non-HDL. Small dense LDL (particle size, ≤ 0.263 relative flotation rate) was most common in M. Triglycerides were lower in M+L than M, and M+L attenuated the negative effect of hyperglycemia on triglycerides and HDL in females. hsCRP, PAI-1, and homocysteine increased over time. However, hsCRP was lower in M+R compared with M or M+L.
Conclusions: Dyslipidemia and chronic inflammation were common in youth with type 2 diabetes and worsened over time. Diabetes treatment, despite some treatment group differences in lipid and inflammatory marker change over time, is generally inadequate to control this worsening risk.
Trial registration: ClinicalTrials.gov NCT00081328.
Figures
Figure 1
Means (mg/dL) by treatment group and annual visit from baseline to 36 months for treatment groups M, M+R, and M+L. Vertical axes are scaled to show differences. Tests were performed using the log transform to normalize the distributions of triglycerides and hsCRP, but means were calculated for the original scale.
Figure 2
Regression of HbA1c (%) on lipid outcomes (mg/dL) for treatment groups M, M+R, and M+L. Data were included at 12-, 24-, and 36-month visits prior to treatment failure. The analysis tested treatment group differences adjusted for BMI. Slopes indicate change in lipid value per unit increase in HbA1c. Tests were performed using the log transform to normalize the distribution of triglycerides, but estimates of slope were calculated for the original scale.
Similar articles
- Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD. Chu NV, et al. Diabetes Care. 2002 Mar;25(3):542-9. doi: 10.2337/diacare.25.3.542. Diabetes Care. 2002. PMID: 11874944 Clinical Trial. - Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes.
Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Reynolds LR, et al. Diabetes Res Clin Pract. 2007 Aug;77(2):180-7. doi: 10.1016/j.diabres.2006.12.011. Epub 2007 Jan 18. Diabetes Res Clin Pract. 2007. PMID: 17239474 Clinical Trial. - Pitavastatin: novel effects on lipid parameters.
Chapman MJ. Chapman MJ. Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X. Atheroscler Suppl. 2011. PMID: 22152282 Review.
Cited by
- Challenges and pitfalls of youth-onset type 2 diabetes.
La Grasta Sabolic L, Marusic S, Cigrovski Berkovic M. La Grasta Sabolic L, et al. World J Diabetes. 2024 May 15;15(5):876-885. doi: 10.4239/wjd.v15.i5.876. World J Diabetes. 2024. PMID: 38766423 Free PMC article. Review. - A1C: Episode 2.
Aung NL. Aung NL. Clin Diabetes. 2024 Spring;42(2):333-336. doi: 10.2337/cd24-0009. Epub 2024 Feb 12. Clin Diabetes. 2024. PMID: 38694251 Review. No abstract available. - Exploring the Surge in Paediatric Type 2 Diabetes in an Inner-City London Centre-A Decade-Long Analysis of Incidence, Outcomes, and Transition.
Abdelhameed F, Giuffrida A, Thorp B, Moorthy MK, Gevers EF. Abdelhameed F, et al. Children (Basel). 2024 Jan 29;11(2):173. doi: 10.3390/children11020173. Children (Basel). 2024. PMID: 38397285 Free PMC article. - 14. Children and Adolescents: Standards of Care in Diabetes-2024.
American Diabetes Association Professional Practice Committee. American Diabetes Association Professional Practice Committee. Diabetes Care. 2024 Jan 1;47(Suppl 1):S258-S281. doi: 10.2337/dc24-S014. Diabetes Care. 2024. PMID: 38078582 Review. - Antihypertensive and Lipid-Lowering Medication Adherence in Young Adults With Youth-Onset Type 2 Diabetes.
Weinstock RS, Trief PM, Burke BK, Wen H, Liu X, Kalichman S, Anderson BJ, Bulger JD. Weinstock RS, et al. JAMA Netw Open. 2023 Oct 2;6(10):e2336964. doi: 10.1001/jamanetworkopen.2023.36964. JAMA Netw Open. 2023. PMID: 37792373 Free PMC article.
References
- UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853 - PubMed
- UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854–865 - PubMed
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–1589 - PubMed
- McGill HC, Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP, Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol 1995;15:431–440 - PubMed
- Gidding SS. Assembling evidence to justify prevention of atherosclerosis beginning in youth. Circulation 2010;122:2493–2494 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR000005/TR/NCATS NIH HHS/United States
- UL1 RR024153/RR/NCRR NIH HHS/United States
- M01-RR00125/RR/NCRR NIH HHS/United States
- UL1 RR025780/RR/NCRR NIH HHS/United States
- M01 RR000069/RR/NCRR NIH HHS/United States
- M01 RR000036/RR/NCRR NIH HHS/United States
- UL1-RR025758/RR/NCRR NIH HHS/United States
- UL1 RR024992/RR/NCRR NIH HHS/United States
- U01 DK061212/DK/NIDDK NIH HHS/United States
- M01 RR014467/RR/NCRR NIH HHS/United States
- U01-DK-61212/DK/NIDDK NIH HHS/United States
- M01-RR00036/RR/NCRR NIH HHS/United States
- M01 RR000084/RR/NCRR NIH HHS/United States
- M01-RR00043-45/RR/NCRR NIH HHS/United States
- U01-DK-61239/DK/NIDDK NIH HHS/United States
- U01 DK061254/DK/NIDDK NIH HHS/United States
- UL1 RR024139/RR/NCRR NIH HHS/United States
- UL1 RR024989/RR/NCRR NIH HHS/United States
- UL1-RR024153/RR/NCRR NIH HHS/United States
- U01-DK-61230/DK/NIDDK NIH HHS/United States
- UL1-RR024989/RR/NCRR NIH HHS/United States
- U01 DK061242/DK/NIDDK NIH HHS/United States
- M01-RR01066/RR/NCRR NIH HHS/United States
- M01 RR001066/RR/NCRR NIH HHS/United States
- U01-DK-61254/DK/NIDDK NIH HHS/United States
- U01 DK061230/DK/NIDDK NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1-RR024139/RR/NCRR NIH HHS/United States
- UL1-RR025780/RR/NCRR NIH HHS/United States
- UL1-RR024992/RR/NCRR NIH HHS/United States
- UL1 TR000448/TR/NCATS NIH HHS/United States
- M01 RR000043/RR/NCRR NIH HHS/United States
- UL1-RR024134/RR/NCRR NIH HHS/United States
- U01-DK-61242/DK/NIDDK NIH HHS/United States
- UL1 RR025758/RR/NCRR NIH HHS/United States
- M01-RR00069/RR/NCRR NIH HHS/United States
- M01-RR14467/RR/NCRR NIH HHS/United States
- M01 RR000125/RR/NCRR NIH HHS/United States
- U01 DK061239/DK/NIDDK NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- M01-RR00084/RR/NCRR NIH HHS/United States
- UL1 TR000130/TR/NCATS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous